[Skip to Navigation]
September 1992

Comparison of Gemfibrozil and Lovastatin in Patients With High Low-Density Lipoprotein and Low High-Density Lipoprotein Cholesterol Levels

Author Affiliations

From the Schools of Pharmacy (Drs McKenney and Barnett) and Medicine (Drs Wright and Proctor), Medical College of Virginia, Virginia Commonwealth University, Richmond. Dr Barnett is now with the US Air Force, Department of Pharmacy, KTTC Medical Center, Keesler Air Force Base, Miss. Dr Wright is now with the Division of Endocrinology and Hypertension, Case Western Reserve University, Cleveland, Ohio.

Arch Intern Med. 1992;152(9):1781-1787. doi:10.1001/archinte.1992.00400210023005

Background.—  The efficacy of gemfibrozil and lovastatin in the treatment of patients who have an elevated low-density lipoprotein cholesterol (LDL-C) level and a low high-density lipoprotein cholesterol (HDL-C) level was compared.

Methods.—  After at least 6 weeks of a choleserol-lowering diet, 17 patients who had a mean baseline LDL-C level above 4.14 mmol/L (160 mg/dL) and an HDL-C level below 1.03 mmol/L (40 mg/dL) received gemfibrozil 600 mg twice daily and lovastatin 20 mg twice daily each for 6 weeks according to a randomized, crossover, double-blind research design.

Results.—  Lovastatin and gemfibrozil reduced LDL-C levels 34% and 9% and raised HDL-C levels 15% and 18%, respectively.

Conclusions.—  Lovastatin is more effective in lowering LDL-C levels and is as effective as gemfibrozil in increasing HDL-C levels in these patients.(Arch Intern Med. 1992;152:1781-1787)

Add or change institution